A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy...
Depressive DisorderMajorThis study was designed to determine if the novel combination of the SSRI, sertraline, and the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable safety profile of SSRIs.
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
Major Depressive DisorderThe purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder
Antidepressant Therapy for Bipolar II Major Depression
Bipolar Type II DisorderThis study examines the relative safety and benefit of antidepressant therapy (versus recommended mood stabilizer therapy)of bipolar type II major depressive episode. We hypothesize that antidepressant therapy will be superior to mood stabilizer therapy with little or no difference in treatment emergent manic symptoms.
A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
Depressive DisorderMajorTo assess the comparative efficacy of sertraline versus venlafaxine XR on measures of quality of life.
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive...
Major Depressive DisorderThe main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in patients with major depressive disorder. This study also includes a double-placebo group (saredutant placebo in combination with escitalopram placebo).
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
Major Depressive DisorderThe primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD. The primary prediction was that LCn-3 fatty acid supplementation would dose-dependently increase prefrontal cortical functional activation during sustained attention and increase regional biochemical indices of cortical metabolism and integrity concentrations in association with reductions in depressive symptoms.
SA4503 8-Week Study in Major Depressive Disorder (MDD)
Depressive DisorderMajorThe purpose of this study is to determine the efficacy of SA4503 compared to placebo in the treatment of subjects with major depressive disorder (MDD). Secondary, to evaluate the safety of SA4503 compared to placebo in subjects with MDD.
Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes...
Major Depressive DisorderThis study will evaluate the efficacy of Vortioxetine in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Vortioxetine.
A Safety, Efficacy and Tolerability Study of SEP-225289
Depressive DisorderMajorTo determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder
Creatine Augmentation Treatment in Major Depressive Disorder Subjects
Major Depressive DisorderGiven 1) the established safety with short-term or long-term supplementation of Cr, 2) its potential usefulness in improving brain energy metabolism, 3) the reported abnormality in brain energy metabolism in MDD subjects, and 4) plausible association between depression and inflammatory mediators, we hypothesize that oral Cr augmentation will help reduce symptoms in MDD patients as well as normalize a deficit in brain energy metabolism and that improvement of MDD and brain energy metabolism will be correlated with inflammatory mediators changes. In this study, we plan to conduct an randomized, double-blind, placebo-controlled augmentation study with creatine in addition to escitalopram. We will assess the efficacy and safety of the Cr augmentation and evaluate changes relevant to brain energy metabolism and inflammatory mediators.